Glaukos Corp’s iLink therapy for the treatment of keratoconus consists of novel single-use drug formulations that are bio-activated by proprietary systems through the delivery of ultraviolet light to the cornea to induce corneal cross-linking designed to strengthen, stabilise and reshape the cornea.
Glaukos Corp today announced that it has commenced a Phase 2 clinical program for its third-generation pharmaceutical platform (iLink) therapy designed to treat keratoconus.
According to the company, its pharmaceutical platform consists of novel single-use drug formulations that are bio-activated by proprietary systems through the delivery of ultraviolet light to the cornea to induce corneal cross-linking designed to strengthen, stabilise and reshape the cornea.
Glaukos’ third-generation pharmaceutical platform therapy is a corneal cross-linking treatment designed to customise the therapeutic capabilities, streamline the patient experience and build upon Glaukos’ first-generation iLink therapy, known as iLink Epi-off, and its second-generation iLink investigational therapy, known as iLink Epi-on.
“As we do with all of our platforms, we continue to drive subsequent generations of future innovation, and we are delighted to announce the commencement of this Phase 2 clinical program for our third-generation iLink therapy,” said Thomas Burns, Glaukos president and CEO.
Burns added that the pharmaceutical platform therapy builds upon existing therapies, noting that the company is looking forward to seeing what the investigational therapy can do for keratoconus patients in its Phase 2 trials.
The company noted that the third-generation pharmaceutical platform therapy Phase 2 clinical program consists of two separate multi-centre, randomly assigned, controlled trials designed to evaluate the safety and efficacy of patient-specific, customised versus non-customised treatment patterns for corneal cross-linking and a new investigational laser-based bio-activation system, respectively.
According to the company, it anticipates it will enrol keratoconus patients across both trials at clinical sites in the United States, Europe, South America and Asia. Both trials are designed to have a primary safety and efficacy follow-up period of 6 months.
AAO 2024: Transient vision loss with Alexander Fein, MD
October 21st 2024Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might be needed to determine the best plan for care.
AAO 2024: Optimal pupil size reduction percentage for near vision improvement in presbyopia
October 21st 2024Jennifer Loh, MD, shared insights from on her presentation at the American Academy of Ophthalmology meeting in Chicago on the effects of CSF-1, which is the lowest effective concentration of pilocarpine approved in the United States.